Categories
Change Password!
Reset Password!
Romosozumab, a monoclonal antibody helps to increase bone formation and reduce bone resorption, and therefore has promising results for bone volume regulation.
Bone‐forming or anabolic therapies can help to decrease the bone fracture risk for example in postmenopausal women with osteoporosis. In this study, romosozumab resulted in significant and rapid improvements in density and mass at spine and hip as compared to teriparatide. These advantageous effects, perceived after 12 months of treatment, comprised of improvements in the trabecular and cortical compartments.
Romosozumab, a monoclonal antibody helps to increase bone formation and reduce bone resorption, and therefore has promising results for bone volume regulation. In an earlier study, romosozumab found to increase areal BMD at the lumbar spine and total hip compared with placebo, alendronate, and teriparatide in postmenopausal women with low bone mass.
In this international, randomized study, the effect of romosozumab on lumbar spine and hip volumetric BMD (vBMD) and BMC at month 12 as evaluated by QCT in patients and has been compared with teroparatide.
Three hundred and sixty seven patients were divided into
groups who were given teriparatide (20 µg once
daily), and romosozumab subcutaneously (210 mg
once-a-month) and a placebo achieved. The QCT
measurements were implemented at the lumbar spine (mean of L1 and
L2 entire vertebral bodies, without the posterior processes)
and hip.
Romosozumab considerably increased integral
vBMD and BMC at the lumbar spine and total hip from baseline as compared with
placebo and teriparatide an year following the treatment. Romosozumab and
teriparatide depicted similar improvements in trabecular vertebral vBMD. The cortical vertebral vBMD gains were higher with
romosozumab than with teriparatide (13.7% versus 5.7%). The trabecular hip vBMD
gains were considerably larger with romosozumab as compared with teriparatide
(10.8% versus 4.2%), however were similar for cortical vBMD. At both the hip
and spine, the cortical BMC gains were greater with romosozumab than with
teriparatide.
The outcomes of this study encourage the continued
clinical analysis of romosozumab as a promising therapy to rapidly decrease the
risk of fracture in the ongoing phase 3 studies.
Journal of Bone and Mineral Research
Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass
Harry K. Genant et al.
Comments (0)